George A. Eldridge - 07 Dec 2022 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)

Role
Officer Title: Chief Financial Officer and Treasurer
Signature
/s/ George A. Eldridge
Issuer symbol
JBIO
Transactions as of
07 Dec 2022
Net transactions value
-$466,176
Form type
4
Filing time
09 Dec 2022, 17:00:25 UTC
Previous filing
02 Dec 2022
Next filing
13 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTE Common Stock Options Exercise $24,903 +11,637 +594% $2.14* 13,597 07 Dec 2022 Direct F1
transaction AVTE Common Stock Sale $137,090 -7,079 -52% $19.37 6,518 07 Dec 2022 Direct F1, F2
transaction AVTE Common Stock Sale $92,993 -4,558 -70% $20.40 1,960 07 Dec 2022 Direct F1, F3
transaction AVTE Common Stock Options Exercise $25,704 +12,011 +613% $2.14* 13,971 08 Dec 2022 Direct F1
transaction AVTE Common Stock Sale $19,314 -960 -6.9% $20.12 13,011 08 Dec 2022 Direct F1, F4
transaction AVTE Common Stock Sale $412 -20 -0.15% $20.58 12,991 08 Dec 2022 Direct F1
transaction AVTE Common Stock Sale $266,974 -11,031 -85% $24.20 1,960 08 Dec 2022 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -11,637 -12% $0.000000 84,656 07 Dec 2022 Common Stock 11,637 $2.14 Direct F1, F6
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -1,887 -2.2% $0.000000 82,769 08 Dec 2022 Common Stock 1,887 $2.14 Direct F1, F6
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -10,124 -20% $0.000000 40,726 08 Dec 2022 Common Stock 10,124 $2.14 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.00 to $19.97, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.02 to $20.56, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.575 to $20.54, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.50, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F6 A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.
F7 A total of 50,850 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on March 22, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Remarks:

Officer Title: Chief Financial Officer and Treasurer